Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Diabetes Care

• Publication date

  2001-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/DIACARE.24.4.631PMID 11315821
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.

  2000cited by this paper
• Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes.

  2000cited by this paper
• Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

  2000cited by this paper
• Insulin analogues and their potential in the management of diabetes mellitus

  1999cited by this paper
• United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.

  1998cited by this paper
• United Kingdom Prospective Diabetes Study 24: A 6-Year, Randomized, Controlled Trial Comparing Sulfonylurea, Insulin, and Metformin Therapy in Patients with Newly Diagnosed Type 2 Diabetes That Could Not Be Controlled with Diet Therapy

  1998cited by this paper
• Insulin analogues.

  1997cited by this paper
• United Kingdom prospective diabetes study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years

  1995cited by this paper
• U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease

  1995cited by this paper
• Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

  1995cited by this paper
• Improving Insulin Therapy: Achievements and Challenges

  1994cited by this paper
• Improving insulin therapy: achievements and challenges.

  1994cited by this paper
• New Directions in Drug Development: Mixtures, Analogues, and Modeling

  1993cited by this paper

• Investigation of new non-toxic inhibitors of fibril formation and preservatives for insulin preparations its analogues.

  2025cites this paper
• Transdermal drugs and delivery strategies: History, advances and future prospects

  2025cites this paper
• New generation agents for glycemic control and diabetic retinopathy progression: what we need to know?

  2025cites this paper
• Clinical perspectives on the frequency of hypoglycemia in treat-to-target randomized controlled trials comparing basal insulin analogs in type 2 diabetes: a narrative review

  2024cites this paper
• Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update.

  2024cites this paper
• Recent advances in transdermal insulin delivery technology: A review.

  2024cites this paper
• NOVEL AGENTS IN THE MANAGEMENT OF DIABETES AND RISK OF WORSENING DIABETIC RETINOPATHY

  2024cites this paper
• Comparison of Insulin Analogs and Human Insulins: A Narrative Review

  2023cites this paper
• Protamine as a barrier against the angiogenic effect of insulin: a possible role of apelin

  2023cites this paper
• The Principles of Insulin Management of Type 2 Diabetes Mellitus

  2023cites this paper
• Injectable Systems for Long-lasting Insulin Therapy.

  2023cites this paper
• Diselenide-bond replacement of the external disulfide bond of insulin increases its oligomerization leading to sustained activity

  2023cites this paper
• Insulin in Frail, Older People with Type 2 Diabetes—Low Threshold for Therapy

  2022cites this paper
• The association of long‐acting insulin analogue use versus neutral protamine Hagedorn insulin use and the risk of major adverse cardiovascular events among individuals with type 2 diabetes: A population‐based cohort study

  2022cites this paper
• Twenty Years of Insulin Gla-100: A Systematic Evaluation of Its Efficacy and Safety in Type 2 Diabetes Mellitus

  2022influential citation
• Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline.

  2022cites this paper
• A Systematic Review Supporting the Endocrine Society Guidelines: Management of Diabetes and High Risk of Hypoglycemia.

  2022cites this paper
• Effects of intensive insulin therapy on the retinal microvasculature in patients with type 2 diabetes mellitus: a prospective observational study

  2022cites this paper
• Correlates of Analog vs Human Basal Insulin Use among Individuals with Type 2 Diabetes: A Cross-Sectional Study.

  2021cites this paper
• Early Worsening of Retinopathy in Type 1 and Type 2 Diabetes After Rapid Improvement in Glycaemic Control: A Systematic Review

  2021cites this paper
• The Chemical Synthesis of Insulin: An Enduring Challenge.

  2021cites this paper
• A novel glucokinase activator TMG-123 causes long-lasting hypoglycemia and impairs spermatogenesis irreversibly in rats.

  2021cites this paper
• Efficacy and safety of different basal and prandial insulin analogues for the treatment of type 2 diabetes: a network meta-analysis of randomized controlled trials

  2021cites this paper
• Kinetics of Phenol Escape from the Insulin R6 Hexamer.

  2021cites this paper
• Nocturnal hypoglycemia in type 1 and type 2 diabetes: an update on prevalence, prevention, pathophysiology and patient awareness

  2021cites this paper
• Severe Hypoglycemia Risk With Long-Acting Insulin Analogs vs Neutral Protamine Hagedorn Insulin.

  2021cites this paper
• Fundamental Toxicological Sciences

  2021cites this paper
• One hundred years of insulin therapy

  2021cites this paper
• Weight gain associated with insulin detemir vs insulin glargine in clinical practice: A retrospective longitudinal cohort study.

  2020cites this paper
• (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.

  2020cites this paper
• Features of postoperative therapy in patients with type ІІ diabetes

  2020cites this paper
• Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea

  2019cites this paper
• Ultrahigh performance liquid chromatography methods facilitate the development of glucose-responsive insulin therapeutics

  2019cites this paper
• Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world

  2019cites this paper
• Effect of once‐weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD‐2 clinical trial

  2019cites this paper
• Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes.

  2019cites this paper
• Reporting of hypoglycaemia in clinical trials of basal insulins: A need for consensus

  2019cites this paper
• Injectable Systems for Long-Lasting Insulin Therapy

  2019cites this paper
• diabetic retinopathy with rapid improvement in systemic glucose control: a

  2018cites this paper
• Insulin Glargine 100 Units/mL Alone or in Combination with Short-Acting Insulin in the Management of Uncontrolled Type 2 Diabetes Mellitus: A Prospective Real-Life Study from Egypt (DIAMOND)

  2018cites this paper
• Pregestational Diabetes in Pregnancy.

  2018cites this paper
• [Effectiveness of one-year insulin glargine and insulin glulisine basal-bolus treatment in people with type 2 diabetes. An analysis from drug reimbursement perspective].

  2018cites this paper
• [Improvement in the glycaemic control of patients after switching from human insulin to insulin glargine-based basal-bolus regimen].

  2018cites this paper
• Comparison of Glycemic Control between Continuous Regular Insulin Infusion and Single-dose Subcutaneous Insulin Glargine Injection in Medical Critically Ill Patients

  2018cites this paper
• Pharmacologic Glycemic Management of Type 2 Diabetes in Adults.

  2018cites this paper
• The role of basal insulin and GLP-1 receptor agonist combination products in the management of type 2 diabetes

  2018cites this paper
• Insulin Initiation and Titration in Patients With Type 2 Diabetes

  2018cites this paper
• A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus

  2018cites this paper
• Relative Contribution of Fasting and Postprandial Blood Glucose in Overall Glycemic Control: Post Hoc Analysis of a Phase IV Randomized Trial

  2018influential citation
• Switching From Pre-mixed Insulin to Regimens with Insulin Glargine in Type 2 Diabetes: A Prospective, Observational Study of Data From Adriatic Countries

  2018cites this paper
• Insulin does not rescue cortical and trabecular bone loss in type 2 diabetic Goto-Kakizaki rats

  2018cites this paper
• Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review

  2018cites this paper
• Analysis of Insulin Analogs and the Strategy of Their Further Development

  2018cites this paper
• A glargin és glulizin inzulinnal folytatott bázis-bolus kezelési rendszer egyéves eredményessége 2-es típusú cukorbetegségben Elemzés a gyógyszerár-támogatás tükrében of one-year insulin glargine and insulin glulisine basal-bolus treatment in people with diabetes

  2018cites this paper
• Biocatalyzed synthesis of antidiabetic drugs: A review

  2018cites this paper
• Effect of Initiation of Basal Insulin Glargine on Glycemic Control in Patients with Diabetes: Real Life Experience from Hong Kong

  2017cites this paper
• Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial

  2017cites this paper
• Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial

  2017cites this paper
• PROOF COVER SHEET

  2017cites this paper
• United States experience of insulin degludec alone or in combination for type 1 and type 2 diabetes

  2017cites this paper
• United States experience of insulin degludec alone or in combination for type 1 and type 2 diabetes

  2017cites this paper
• Metabolic decompensation in older people

  2017cites this paper
• Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy.

  2017cites this paper
• Effect of insulin glargine on recreational physical activity and TV viewing: Analysis of the randomised ORIGIN trial.

  2017cites this paper
• Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis

  2017cites this paper
• Determinants of weight change in patients on basal insulin treatment: an analysis of the DIVE registry

  2017cites this paper
• The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes

  2017cites this paper
• ‘Borono-lectin’ based engineering as a versatile platform for biomedical applications

  2017cites this paper
• Insulin Degludec/Liraglutide

  2017cites this paper
• Hypoglycemic episodes in cats with diabetes mellitus: 30 cases (2013–2015)

  2017cites this paper
• Insulin glargine 300 units/mL: a guide for healthcare professionals involved in the management of diabetes

  2017cites this paper
• Clinical outcomes of switching from insulin glargine to NPH insulin in indigent patients at a charitable pharmacy: The Charitable Insulin NPH: Care for the Indigent study.

  2017cites this paper
• The Affordable Care Act and Diabetes Diagnosis and Care: Exploring the Potential Impacts

  2016cites this paper
• Projected Cost-Effectiveness of Liraglutide, a Glucagon-Like Insulin Peptide-1Analogue in Comparison to Insulin Glargine in Type 2 Diabetes Patients withSuboptimal Glycaemic Control in Malaysia

  2016cites this paper
• Morphometric characteristic of the pancreatic islets in the treatment of experimental diabetes with insulin

  2016cites this paper
• Pursuit of a perfect insulin

  2016cites this paper
• Role of incretin‐based therapies and sodium‐glucose co‐transporter‐2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira

  2016cites this paper
• Controlled release of biologics for the treatment of type 2 diabetes.

  2016cites this paper
• The past, present, and future of basal insulins

  2016cites this paper
• Advances in Insulin Therapy: A Review of New Insulin Glargine 300 Units/mL in the Management of Diabetes

  2016cites this paper
• Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis

  2016cites this paper
• Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes

  2016cites this paper
• Recombinant Human Insulins – Clinical Efficacy and Safety in Diabetes Therapy

  2016cites this paper
• Safety of insulin analogues as compared with human insulin in pregnancy

  2016cites this paper
• Efficacy and safety assessment of basal supported oral therapy (BOT) with insulin glargine in a real-life clinical setting, stratified by concomitant orally administered antidiabetic agent (OAD) regimens including dipeptidyl peptidase-4 inhibitor (DPP-4i): subanalysis of the ALOHA2 study, drug-use s

  2016cites this paper
• Cost‐effectiveness of a risk‐based secondary screening programme of type 2 diabetes

  2016cites this paper
• Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial

  2016cites this paper
• Treatment Strategies for Type 2 Diabetes Based on Incretin Action

  2016cites this paper
• Excess weight gain during insulin pump therapy is associated with higher basal insulin doses

  2016cites this paper
• Comparison of PEGylated FGF-21 with insulin glargine for long-lasting hypoglycaemic effect in db/db mice.

  2015cites this paper
• Insulin therapy in type 1 diabetes.

  2015cites this paper
• Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates

  2015cites this paper
• The use of insulin detemir during pregnancy: a safety evaluation

  2015influential citation
• Mechanisms of hypoglycemia unawareness and implications in diabetic patients.

  2015cites this paper
• The Role of Hormones in Glucose Homeostasis and Diabetes Treatment

  2015cites this paper
• Pharmacologic Treatment of Type 2 Diabetes

  2015cites this paper
• Insulinothérapie chez le diabétique de type 2 : insulines conventionnelles ou analogues ?

  2015cites this paper
• Canine Diabetes Mellitus

  2015cites this paper
• Engineering synthetically modified insulin for glucose-responsive diabetes therapy

  2015cites this paper
• Clinical trials comparing basal insulins Glargine versus NPH

  2015cites this paper